344 related articles for article (PubMed ID: 36333773)
1. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
[TBL] [Abstract][Full Text] [Related]
3. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; ; Obermair A
Contemp Clin Trials; 2014 Sep; 39(1):14-21. PubMed ID: 24999075
[TBL] [Abstract][Full Text] [Related]
4. Metformin for endometrial hyperplasia.
Clement NS; Oliver TR; Shiwani H; Sanner JR; Mulvaney CA; Atiomo W
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012214. PubMed ID: 29077194
[TBL] [Abstract][Full Text] [Related]
5. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
6. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914).
Xu Z; Yang B; Guan J; Shan W; Liao J; Shao W; Chen X
J Gynecol Oncol; 2023 Jan; 34(1):e32. PubMed ID: 36562136
[TBL] [Abstract][Full Text] [Related]
8. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
9. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
10. Metformin for endometrial hyperplasia.
Shiwani H; Clement NS; Daniels JP; Atiomo W
Cochrane Database Syst Rev; 2024 May; 5(5):CD012214. PubMed ID: 38695827
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
[TBL] [Abstract][Full Text] [Related]
12. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
[TBL] [Abstract][Full Text] [Related]
13. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
14. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
15. Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol.
Fernandez-Montoli ME; Sabadell J; Contreras-Perez NA
Adv Ther; 2021 May; 38(5):2717-2731. PubMed ID: 33830463
[TBL] [Abstract][Full Text] [Related]
16. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
19. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M; Robledo KP; Gebski V; Armes JE; Alizart M; Cummings M; Chen C; Leung Y; Sykes P; McNally O; Oehler MK; Walker G; Garrett A; Tang A; Land R; Nicklin JL; Chetty N; Perrin LC; Hoet G; Sowden K; Eva L; Tristram A; Obermair A
Gynecol Oncol; 2021 Apr; 161(1):143-151. PubMed ID: 33762086
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of levonorgestrel-releasing intrauterine device present during controlled ovarian stimulation in patients with early stage endometrioid adenocarcinoma and atypical endometrial hyperplasia after fertility-sparing treatments: 10-year experience in one tertiary hospital in China.
Yin J; Li Y; Wang H; Wang W; Gu Y; Jin Y; Deng C; Pan L
Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():83-88. PubMed ID: 36436458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
